

Characterization of the short isoform of Helios overexpressed in patients with T-cell malignancies

Takayuki Tabayashi,¹ Fumihiko Ishimaru,^{1,3} Minoru Takata,² Itaru Kataoka,¹ Koichi Nakase,¹ Teruhiko Kozuka¹ and Mitsune Tanimoto¹

¹Department of Medicine, University of Okayama, 2-5-1 Shikatacho, Okayama 700-8558; ²Department of Human Genetics, University of Hiroshima, 1-2-3 Kasumi, Minamiku, Hiroshima 734-8553, Japan

(Received August 30, 2006/Revised October 4, 2006/Accepted October 5, 2006/Online publication December 1, 2006)

In an earlier report, we demonstrated overexpression of a short isoform of Helios, Hel-5, which lacks three of four N-terminal zinc fingers, in patients with adult T-cell leukemia/lymphoma. Here, we characterized Hel-5 using immunoprecipitation, and gel shift and luciferase promoter assays, and found that Hel-5 lacks the repressor function observed with a full-length isoform of Helios. Moreover, Hel-5 associates with the full-length isoforms of the *Ikaros* gene family, *Ikaros*, *Aiolos* and *Helios*, and inhibits their DNA binding activity when present in excess, leading to dominant-negative effects on the full-length isoforms of the *Ikaros* gene family. Our results suggest a critical role for Helios in the mechanism of leukemogenesis. (*Cancer Sci* 2007; 98: 182–188)

Gene targeting studies in mice have shown that the transcription factor *Ikaros* plays a critical role in lymphoid development and proliferation.^(1–3) We examined the expression of *Ikaros* and found overexpression of a dominant-negative isoform, Ik-6, in patients with blast crisis of chronic myelogenous leukemia⁽⁴⁾ and B-cell acute lymphoblastic leukemia.⁽⁵⁾ By alternative splicing,⁽⁶⁾ *Ikaros* encodes DNA binding proteins that dimerize both with each other⁽⁷⁾ and with the other members of the *Ikaros* gene family, *Aiolos*^(8,9) and *Helios*.^(10,11) *Ikaros* family proteins dimerize via the C-terminal zinc fingers, whereas the N-terminal zinc fingers mediate DNA binding. Isoforms that have less than two N-terminal zinc fingers are reported to have a dominant-negative effect on isoforms with more than two N-terminal zinc fingers.⁽⁷⁾ Recently, we found overexpression of short isoforms of Helios, which lacks three of the four N-terminal zinc fingers, in patients with T-cell acute lymphoblastic leukemia⁽¹²⁾ and adult T-cell leukemia/lymphoma (ATLL).⁽¹³⁾ None of the Human T-lymphotropic Virus (HTLV-I) carriers analyzed demonstrated overexpression of short isoforms of Helios, suggesting an important role for Helios in progression of the disease from an HTLV-I carrier to ATLL. In the present report, we characterize Hel-5, which is presumed to be a dominant-negative isoform of Helios, to clarify the underlying mechanism of leukemogenesis.

Materials and Methods

Immunoprecipitation. Full-length isoforms (HA-Ik-1, FLAG-Aiolos or HA-Hel-1) and short isoforms (Ik-6 or Hel-5) were cotransfected into 293T cells using Lipofectamine Reagent (Invitrogen, Carlsbad, CA, USA). Immunoprecipitation was carried out as described previously,⁽⁷⁾ using ImmunoPure Immobilized Protein A (Pierce Biotechnology, Rockford, IL, USA) and anti-hemagglutinin (HA) antibody (Roche, Basel, Switzerland), or anti-FLAG M2 affinity gel (Sigma-Aldrich, St Louis, MO, USA). Resolved proteins were transferred to a nitrocellulose filter and probed with anti-Ikaros or anti-Helios antibodies. Anti-rabbit IgG, peroxidase-linked whole antibody (Amersham Biosciences, Piscataway, NJ) and ECL Western Blotting Detection Reagents (Amersham Biosciences) were used to detect hybridizing proteins.

Electrophoretic mobility shift assay. Gel shift assays were carried out as described previously.⁽¹⁴⁾ Single-stranded complementary sense and antisense oligonucleotides from the *Ikaros* binding site (Ik-BS4: tcagcttttgggaatgtattcctgtca)⁽⁶⁾ were synthesized and used to generate double-stranded oligonucleotide probes. In selected experiments, 100-fold molar excess unlabeled double-stranded oligonucleotide or the antibody were added to binding reactions.

Luciferase assay. For promoter assays, pGL3 luciferase reporter vectors (Promega, Madison, WI, USA) were modified. Four copies of the *Ikaros* binding site (IkBS2: tcagcttttgggaatctctgtca)⁽⁶⁾ were introduced upstream of the TATA box of the pGL3-Enhancer Vector (4xIkBS2-TATA-Luc). The TATA box was then substituted for SV40 promoter (4xIkBS2-SV40-Luc) or TK promoter (4xIkBS2-TK-Luc). Into 293T cells, 1 µg of reporter vector and 0.1 µg of control vector, pRL-TK, were cotransfected, and promoter activity was analyzed using the Dual-Luciferase Reporter Assay System (Promega). Promoter activity was calculated as the firefly luciferase activity of the reporter vector divided by the renilla luciferase activity of the control vector. Dominant-negative effect of the short isoform was shown as percentage inhibition against repressor function of the full-length isoform.

Results

Homo- and hetero-dimerization of the *Ikaros* gene family.

The carboxy-terminal zinc fingers of the *Ikaros* gene family members, *Ikaros*, *Aiolos* and *Helios*, which mediate their homodimerization and heterodimerization, are highly conserved.^(7,8,10,11) In 293T cell lysates cotransfected with HA-Ik-1 and Ik-6 (Fig. 1a), both *Ikaros* isoforms were found in complexes immunoprecipitated with anti-HA antibody (Fig. 2a, lane 3). Moreover, either Ik-1 or




Fig. 1. Diagrammatic representation of (a) *Ikaros* and (b) *Helios* isoforms. The four N-terminal zinc fingers and the two C-terminal zinc fingers are shown as solid perpendicular boxes.

³To whom correspondence should be addressed.
E-mail: ishimaru@md.okayama-u.ac.jp




Fig. 2. Homo- and heterodimerization of the *Ikaros* gene family. Constructs containing genes encoding tagged full-length isoforms of Ikaros, Aiolos or Helios (Ik-1, Aiolos or Hel-1, respectively), which are shown in the box, and the short isoforms of Ikaros or Helios (Ik-6 or Hel-5) were expressed in 293T cells. Heterodimerization of (a) Hel-1/Ik-1 or Ik-6 (lanes 1 and 2) and (b) Ik-1/Hel-1 or Hel-5 (lanes 1 and 2) were demonstrated by precipitation with anti-hemagglutinin (HA) antibody. Homodimerization of Ikaros or Helios proteins were also demonstrated by precipitation with anti-HA antibody: (a) lane 3, (b) lane 3. Heterodimerization of (a) Ikaros/Aiolos (lanes 4 and 5) and (b) Aiolos/Helios (lanes 4 and 5) were demonstrated by precipitation with anti-FLAG antibody. Anti-Ikaros or -Helios antibody was used to detect (a) Ik-1 and Ik-6 or (b) Hel-1 and Hel-5 in precipitated complexes.

Ik-6 coprecipitated with HA-Hel-1 (Fig. 2a, lanes 1 and 2) and FLAG-Aiolos (Fig. 2a, lanes 4 and 5). Similarly, in 293T cells cotransfected with HA-Hel-1 and Hel-5 (Fig. 1b), both Helios isoforms were found in complexes immunoprecipitated with anti-HA antibody (Fig. 2b, lane 3), and either Hel-1 or Hel-5 coprecipitated with HA-Ik-1 (Fig. 2b, lanes 1 and 2) and FLAG-Aiolos (Fig. 2b, lanes 4 and 5). These results suggest that the

short isoforms of the *Ikaros* gene family, Ik-6 and Hel-5, dimerize with the full-length isoforms, Ik-1, Aiolos or Hel-1.

DNA binding properties of the *Ikaros* gene family. Next, we investigated the DNA-binding affinity of the *Ikaros* gene family. Whole-cell lysates from 293T cells transfected with Ik-1, Aiolos or Hel-1 demonstrated major shifted bands (Fig. 3, lanes 1, 6 and 11, respectively), which were inhibited with 100-fold molar excess unlabeled double-stranded oligonucleotide and confirmed to be supershifted by anti-Ikaros, -Aiolos or -Helios antibodies (data not shown). Interestingly, the mobilities of members of the *Ikaros* gene family were different from each other, although they bind the same probe.⁽⁶⁾ As expected from a previous report,⁽⁷⁾ the major shifted bands were not observed with whole-cell lysates from 293T cells transfected with Ik-6 or Hel-5 (data not shown). Mixing a consistent amount of Ik-1 with increasing amounts of Ik-6 showed a significant reduction of the DNA-binding activity of Ik-1 (Fig. 3, lanes 2 and 3). Similarly, mixing a consistent amount of Hel-1 with increasing amounts of Hel-5 showed a marked reduction of the DNA-binding activity of Hel-1 (Fig. 3, lanes 14 and 15). Moreover, blocking the DNA-binding activity of full-length isoforms of other *Ikaros* gene family members, Aiolos and Helios with Ik-6 (Fig. 3, lanes 7–8 and 12–13, respectively) and Ikaros and Aiolos with Hel-5 (Fig. 3, lanes 4–5 and 9–10, respectively), was also observed.

Loss of repressor function of short isoforms of the *Ikaros* gene family. As reported previously,⁽¹⁵⁾ *Ikaros* gene family members, Ikaros, Aiolos and Helios, could not activate a minimal promoter that consists of only a TATA box that is under the control of four copies of the Ikaros binding site (4xIkBS2-TATA-Luc, data not shown). However, in contrast to a previous report that demonstrated activation by the *Ikaros* gene family,^(7,8,15,16) full-length isoforms, Ik-1, Aiolos and Hel-5, repressed the reporter in which TK or SV40 promoters were substituted for the TATA box (4xIkBS2-TK-Luc or 4xIkBS2-SV40-Luc, respectively). These repressor functions of the *Ikaros* gene family appeared dose dependent (Fig. 4a–c). Ik-1 repressed TK promoter activity from 14.4 down to 5.6, 4.0, 3.0 and 2.2 with increasing amounts (Fig. 4a; $n = 5$). Aiolos repressed TK promoter activity from 16.1 down to 12.3, 9.4, 7.4 and 5.5 with increasing amounts (Fig. 4b; $n = 5$), and Hel-1 repressed TK promoter activity from 10.4 down to 6.0, 4.7, 3.9 and 3.2 with increasing amounts (Fig. 4c; $n = 5$). Similar results were obtained with the SV40 promoter (Fig. 4a–c; $n = 5$). However, Ik-6 and Hel-5, short isoforms of the *Ikaros*




Fig. 3. DNA binding properties of the *Ikaros* gene family. *Ikaros* gene family proteins bind the same DNA sequence (Ik-BS4: tcagctttgggaatgtattccctgtca) with high affinity. The shifted bands are indicated by arrows. Consistent amounts of full-length isoforms of Ikaros, Aiolos or Helios (Ik-1, Aiolos or Hel-1, respectively) and increasing amounts of the short isoforms of Ikaros or Helios (Ik-6 or Hel-5, respectively) were expressed in 293T cells, and whole-cell lysates were extracted. The molar ratios of full-length and short isoforms are shown.




Fig. 4. Repressor functions of the *Ikaros* gene family. Full-length isoforms of (a) Ikaros, (b) Aiolos or (c) Helios (Ik-1, Aiolos or Hel-1, respectively) were cotransfected with a reporter vector, 4xIkBS2-TK-Luc (TK) or 4xIkBS2-SV40-Luc (SV40), and an internal control vector. The empty vector was used to supplement the total amounts of transfected expression vector, and the molar ratios are shown. Promoter activity was calculated as the firefly luciferase activity of the reporter vector divided by the renilla luciferase activity of the control vector.

gene family, could not demonstrate the repressor function observed with the full-length isoforms (Fig. 5a,b). Ik-1 repressed TK promoter activity from 15.6 down to 3.1; however, Ik-6 could not show repressor activity at 13.1, and the difference was statistically significant (Fig. 5a; $n = 5$, $P = 0.01$). Hel-1 repressed TK promoter activity from 11.9 down to 4.1, in contrast Hel-5 could not demonstrate repressor activity at 9.7; again the difference was statistically significant (Fig. 5b; $n = 5$, $P = 0.0001$). Similar results were obtained with the SV40 promoter (Fig. 5a,b; $n = 5$, $P < 0.001$).

Functional interactions between full-length isoforms and short isoforms of the *Ikaros* gene family. Finally, we examined promoter activity mixing consistent amounts of full-length isoforms with increasing amounts of short isoforms, as Ik-6 was reported to be a dominant-negative isoform.^(7,8) We found that there was an interfering activity of Ik-6 on the repressor function of Ik-1 (Fig. 6a). TK promoter activity at 12.5 was repressed down to 5.3 by Ik-1, and the addition of Ik-6 in increasing amounts canceled the repressor function of Ik-1, which went up to 8.4, 9.3 and 9.1 (56% inhibition; Fig. 6a, $n = 5$). SV40 promoter activity at 4.4




Fig. 5. Loss of repressor function of short isoforms of the *Ikaros* gene family. The same amounts of the empty vector, the short isoform of the *Ikaros* gene family, (a) Ik-6 or (b) Hel-5, or the full-length isoform of the *Ikaros* gene family, (a) Ik-1 or (b) Hel-1, were cotransfected with a reporter vector, 4xIkBS2-TK-Luc (TK) or 4xIkBS2-SV40-Luc (SV40), and an internal control vector. Promoter activity was calculated as the firefly luciferase activity of the reporter vector divided by the renilla luciferase activity of the control vector. Statistical analysis was carried out using Student's *t*-test ($n = 5$).

was repressed down to 0.7 by Ik-1, and the addition of Ik-6 in increasing amounts blocked the repressor function of Ik-1, which went up to 1.5, 2.1 and 2.4 (46% inhibition; Fig. 6a, $n = 5$). In contrast to a previous report,⁽⁸⁾ similar results could not be obtained with other *Ikaros* gene family members, Aiolos and Hel-1 (Fig. 6b–c). However, Hel-5 demonstrated its presumed dominant-negative effect on the repressor function of the full-length isoforms of the *Ikaros* gene family, although the effect appeared to be variable (Fig. 7a–c). SV40 promoter activity at 5.1 was repressed down to 0.7 by Ik-1, and the addition of increasing amounts of Hel-5 could cancel the repressor function of Ik-1, which went up to 1.4, 1.8 and 1.9 (27% inhibition; Fig. 7a; $n = 5$). SV40 promoter activity at 4.2 was repressed down to 1.5 by Hel-1, and the addition of increasing amounts of Hel-5 could effectively block the repressor function of Hel-1, which went up to 1.8, 2.2 and 2.5 (37% inhibition; Fig. 7c; $n = 5$).

Discussion

This report presents the first analysis of the function of a short isoform of Helios, Hel-5, which was found to be overexpressed with high frequency in ATLL patients.⁽¹³⁾ Our results suggest that the full-length isoform of Helios acts as a repressor and that the short isoform of Helios lacks the repressor function. Moreover, the short isoform of Helios associates with full-length isoforms of the *Ikaros* gene family and inhibits their DNA binding activity,

leading to a dominant-negative effect for Hel-5 on full-length isoforms of the *Ikaros* gene family.

Whereas *Ikaros* family members are important transcription factors in the lymphoid system, previously published experiments were all carried out in 293T cells because of their easy transfectability. However, our results contradict previous reports,^(7,8) and the dominant-negative effect of short isoforms appear to be variable depending on the conditions examined. In detail, we could not observe promoter activation with the full-length isoform of *Ikaros* gene family members.^(7,8) Sun *et al.* reported that Ik-1 stimulates expression of the reporter under the control of four copies of an *Ikaros* recognition site (4xIkBS1: tcagcttttgggaataccctgtca-*tk*-CAT⁽⁶⁾) in NIH 3T3 cells.⁽⁷⁾ Using exactly the same system, Morgan *et al.* reported that Aiolos is a more potent transcriptional activator than *Ikaros*.⁽⁸⁾ We used a quite similar system, and the differences were minimal: DNA-binding sequences of *Ikaros* (IkBS1 vs IkBS2), expression vector (CDM8 vs pGL3), reporter gene (CAT vs luciferase) and cell line (NIH 3T3 vs 293T). Moreover, the dominant-negative effect of Ik-6 was not as dramatic as reported previously.^(7,8) Sun *et al.* reported that coexpression of Ik-1 with excess amounts of Ik-6 strongly interfered with its ability to activate transcription.⁽⁷⁾ Morgan *et al.* reported similar results with Aiolos, demonstrating the dominant-negative effect of Ik-6 on other members of the *Ikaros* gene family.⁽⁸⁾ At present, the reasons for these discrepancies are not clear, and further attempts to establish a lymphoid system for the *Ikaros* gene family are necessary.




Fig. 6. Functional interactions between full-length isoforms of the *Ikaros* gene family and a short isoform, Ik-6. Full-length isoforms of (a) Ikaros, (b) Aiolos or (c) Helios (Ik-1, Aiolos or Hel-1, respectively) and a short isoform of Ikaros (Ik-6) were cotransfected with a reporter vector, 4xIkBS2-TK-Luc (TK) or 4xIkBS2-SV40-Luc (SV40), and an internal control vector. The empty vector was used to supplement the total amounts of transfected expression vector, and the molar ratios are shown. Promoter activity was calculated as the firefly luciferase activity of the reporter vector divided by the renilla luciferase activity of the control vector.

Nevertheless, Hel-5 obviously lost the repressor function that would normally suppress the targeted genes, suggesting Helios as a candidate tumor suppressor. Further analyses of the short isoforms of the *Ikaros* gene family overexpressed in patients with hematological malignancies are warranted.

Acknowledgments

We appreciate the generous gifts from Dr Smale (HA-Ik-1, HA-Hel-1, anti-Ikaros antibody and anti-Helios antibody) and Dr Georgopoulos (FLAG-Aiolos and anti-Aiolos antibody).




Fig. 7. Functional interactions between full-length isoforms of the *Ikaros* gene family and a short isoform, Hel-5. Full-length isoforms of (a) *Ikaros*, (b) *Aiolos* or (c) *Helios* (Ik-1, *Aiolos* or Hel-1, respectively) and a short isoform of *Helios* (Hel-5) were cotransfected with a reporter vector, 4xIkBS2-TK-Luc (TK) or 4xIkBS2-SV40-Luc (SV40), and an internal control vector. The empty vector was used to supplement the total amounts of transfected expression vector, and the molar ratios are shown. Promoter activity was calculated as the firefly luciferase activity of the reporter vector divided by the renilla luciferase activity of the control vector.

References

- Georgopoulos K, Bigby M, Wang J-H *et al.* The *Ikaros* gene is required for the development of all lymphoid lineages. *Cell* 1994; **79**: 143–56.
- Winandy S, Wu P, Georgopoulos K. A dominant mutation in the *Ikaros* gene leads to rapid development of leukemia and lymphoma. *Cell* 1995; **83**: 289–99.
- Wang J-H, Nichogiannopoulou A, Wu L *et al.* Selective defects in the development of the fetal and adult lymphoid system in mice with an *Ikaros* null mutation. *Immunity* 1996; **5**: 537–49.
- Nakayama H, Ishimaru F, Avitahl N *et al.* Decreases in *Ikaros* activity correlate with blast crisis in patients with chronic myelogenous leukemia. *Cancer Res* 1999; **59**: 3931–4.
- Nakase K, Ishimaru F, Avitahl N *et al.* Dominant-negative isoform of *Ikaros*

- gene in patients with adult B-cell acute lymphoblastic leukemia. *Cancer Res* 2000; **60**: 4062–5.
- 6 Molnar A, Georgopoulos K. The *Ikaros* gene encodes a family of functionally diverse zinc finger DNA binding proteins. *Mol Cell Biol* 1994; **14**: 8292–303.
- 7 Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. *EMBO J* 1996; **15**: 5358–69.
- 8 Morgan B, Sun L, Avitahl N *et al.* Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation. *EMBO J* 1997; **16**: 2004–13.
- 9 Wang J-H, Avitahl N, Cariappa A *et al.* Aiolos regulates B cell activation and maturation to effector state. *Immunity* 1998; **9**: 543–53.
- 10 Hahm K, Cobb BS, McCarty AS *et al.* Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. *Genes Dev* 1998; **12**: 782–96.
- 11 Kelley CM, Ikeda T, Koipally J *et al.* Helios, a novel dimerization partner of Ikaros expressed in the earliest hematopoietic progenitors. *Curr Biol* 1998; **8**: 508–15.
- 12 Nakase K, Ishimaru F, Fujii K *et al.* Overexpression of novel short isoforms of Helios in a patient with T-cell acute lymphoblastic leukemia. *Exp Hematol* 2002; **30**: 313–17.
- 13 Fujii K, Ishimaru F, Nakase K *et al.* Over-expression of short isoforms of Helios in patients with adult T-cell leukaemia/lymphoma. *Br J Haematol* 2003; **120**: 986–9.
- 14 Ishimaru F, Mari B, Shipp MA. The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. *Blood* 1997; **89**: 4136–45.
- 15 Koipally J, Heller EJ, Seavitt JR, Georgopoulos K. Unconventional potentiation of gene expression by Ikaros. *J Biol Chem* 2002; **277**: 13007–15.
- 16 Koipally J, Georgopoulos K. Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity. *J Biol Chem* 2000; **275**: 19594–602.